- Home
- ICCM vs AEON Comparison
ICCM vs AEON Comparison
Compare ICCM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | AEON |
|---|---|---|
| Founded | 2006 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 9.6M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICCM | AEON |
|---|---|---|
| Price | $2.21 | $0.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $7.20 |
| AVG Volume (30 Days) | 89.0K | ★ 3.2M |
| Earning Date | 05-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $139.51 | N/A |
| Revenue Next Year | $75.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.18 |
| 52 Week High | $9.54 | $1.45 |
Technical Indicators
Market Signals| Indicator | ICCM | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 33.57 | 39.61 |
| Support Level | $2.15 | $0.18 |
| Resistance Level | $3.59 | $0.33 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 10.45 | 38.98 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.